- Home
- OMCL vs MIRM Comparison
OMCL vs MIRM Comparison
Compare OMCL & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCL
- MIRM
- Stock Information
- Founded
- OMCL 1992
- MIRM 2018
- Country
- OMCL United States
- MIRM United States
- Employees
- OMCL N/A
- MIRM N/A
- Industry
- OMCL Computer Manufacturing
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- OMCL Technology
- MIRM Health Care
- Exchange
- OMCL Nasdaq
- MIRM Nasdaq
- Market Cap
- OMCL 1.3B
- MIRM 2.5B
- IPO Year
- OMCL 2001
- MIRM 2019
- Fundamental
- Price
- OMCL $29.84
- MIRM $50.30
- Analyst Decision
- OMCL Buy
- MIRM Strong Buy
- Analyst Count
- OMCL 6
- MIRM 9
- Target Price
- OMCL $44.83
- MIRM $66.22
- AVG Volume (30 Days)
- OMCL 472.7K
- MIRM 468.1K
- Earning Date
- OMCL 07-31-2025
- MIRM 08-06-2025
- Dividend Yield
- OMCL N/A
- MIRM N/A
- EPS Growth
- OMCL N/A
- MIRM N/A
- EPS
- OMCL 0.45
- MIRM N/A
- Revenue
- OMCL $1,135,755,000.00
- MIRM $379,251,000.00
- Revenue This Year
- OMCL $3.84
- MIRM $35.83
- Revenue Next Year
- OMCL $4.07
- MIRM $16.83
- P/E Ratio
- OMCL $65.79
- MIRM N/A
- Revenue Growth
- OMCL 3.00
- MIRM 69.31
- 52 Week Low
- OMCL $22.66
- MIRM $33.52
- 52 Week High
- OMCL $55.75
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- OMCL 53.19
- MIRM 55.85
- Support Level
- OMCL $28.80
- MIRM $47.89
- Resistance Level
- OMCL $30.57
- MIRM $51.93
- Average True Range (ATR)
- OMCL 0.78
- MIRM 1.44
- MACD
- OMCL 0.10
- MIRM -0.30
- Stochastic Oscillator
- OMCL 74.56
- MIRM 39.98
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.